Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders
Actimed Therapeutics to present on development of its lead asset in treatment of cancer cachexia at the Society on Sarcopenia, Cachexia and Wasting Disorders